Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation

Journal of Thoracic and Cardiovascular Surgery

Volumn 135, Issue 3, 2008, Pages 594-602

  Ailawadi, Gorav ^a   Smith, Philip W ^a   Oka, Tomomi ^a   Wang, Hongkun ^b   Kozower, Benjamin D ^a   Daniel, Thomas M ^a   Kron, Irving L ^a   Jones, David R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SCHOOL CHILD;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; BRONCHIOLITIS OBLITERANS; CAUSE OF DEATH; COHORT STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 40149104213     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2007.10.044     Document Type: Article

References (20)

1. Knoop C., and Estenne M. Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med 27 (2006) 521-533
2. Trulock E.P., Edwards L.B., Taylor D.O., Boucek M.M., Keck B.M., and Hertz M.I. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report-2006. J Heart Lung Transplant 25 (2006) 880-892
3. DeVito Dabbs A., Hoffman L.A., Iacono A.T., Wells C.L., Grgurich W., Zullo T.G., et al. Pattern and predictors of early rejection after lung transplantation. Am J Crit Care 12 (2003) 497-507
4. Heng D., Sharples L.D., McNeil K., Stewart S., Wreghitt T., and Wallwork J. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 17 (1998) 1255-1263
5. Hachem R.R., Khalifah A.P., Chakinala M.M., Yusen R.D., Alough A.A., Mohanakumar T., et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 80 (2005) 1406-1413
6. Garrity Jr. E.R., Villanueva J., Bhorade S.M., Husain A.N., and Vigneswaran W.T. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 71 (2001) 773-777
7. Brock M.V., Borja M.C., Ferber L., Orens J.B., Anzcek R.A., Krishnan J., et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 20 (2001) 1282-1290
8. Burton C.M., Anderson C.B., Jensen A.S., Iversen M., Milman N., Boesgaard S., et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J Heart Lung Transplant 25 (2006) 638-647
9. Lischke R., Simonek J., Davidova R.D., Schutzner J., Stolz A.J., Vojacek J., et al. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. Transplant Proc 39 (2007) 205-212
10. Billingham M.E., Cary N.R., Hammond M.E., Kemnitz J., Marboe C., McCallister H.A., et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 9 (1990) 587-593
11. Shield C.F., Edwards E.B., Davies D.B., and Daily O.P. Antilymphocyte induction therapy in cadaver renal transplantation: a retrospective, multicenter United Network for Organ Sharing Study. Transplantation 63 (1997) 1257-1263
12. Stratta R.J., Alloway R.R., Hodge E., and Lo A. Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. Clin Transplant 16 (2002) 60-68
13. Hopkins P.M., Aboyoun C.L., Chhajed P.N., Malouf M.A., Plit M.L., Rainer S.P., et al. Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant. recipients. J Heart Lung Transplant 21 (2002) 1062-1067
14. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338 (1998) 161-165
15. Beniaminovitz A., Itescu S., Lietz K., Donovan M., Burke E.M., Groff B.D., et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342 (2000) 613-619
16. Carlsen J., Johansen M., Boesgaard S., Andersen C.B., Arendrup H., Aldershvilet J., et al. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant 24 (2005) 296-302
17. McNeil K., Glanville A.R., Wahlers T., Knoop C., Speich R., Mamelok R.D., et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 81 (2006) 998-1003
18. Sarahrudi K., Estenne M., Corris P., Niedermayer J., Knoop C., Glanville A., et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 137 (2004) 1126-1132
19. Zuckermann A., Reichenspurner H., Birsan T., Treede H., Deviatko E., Reichart B., et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg 125 (2003) 891-900
20. Caillard S., Dharnidharka V., Agodoa L., Bohen E., and Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80 (2005) 1233-1243